2010-07-12 11:37 Bristol-Myers Squibb (PARIS, July 7, 2010) – Bristol-Myers Squibb announced that on 5th of July, the European Commission has approved boosted REYATAZ (atazanavir sulfate) capsules to treat HIV-1 infection in paediatric patients aged six to eighteen years and greater than 15 kg, as part of combination HIV therapy.1 This decision grants marketing authorisation in the 27 countries of the European Union.